Seres Therapeutics, Inc.
MCRB
$7.76
-$0.20-2.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -286.92% | 141.32% | -160.75% | 309.00% | -117.61% |
| Total Depreciation and Amortization | 795.98% | -1.42% | -1.58% | -89.54% | 632.55% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -100.00% |
| Total Other Non-Cash Items | -169.61% | 4.61% | -9.46% | 242.89% | 97.06% |
| Change in Net Operating Assets | 52.60% | -1,156.12% | 109.42% | 61.12% | -214.04% |
| Cash from Operations | -766.82% | 116.60% | -149.38% | 169.21% | -12.12% |
| Capital Expenditure | -262.50% | 95.58% | -432.35% | 62.22% | 30.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -100.00% |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 2,362.50% | 95.58% | -432.35% | 62.22% | -100.06% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | 20,649.18% | -- | -100.00% | -32.07% | -89.80% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 20,649.18% | -- | -100.00% | -32.07% | 101.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -182.87% | 116.77% | -148.01% | 175.35% | -744.74% |